Innate immunity and regulatory T-cells in human Chagas disease: What must be understood?

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue SUPPL. 1, 2009, Pages 246-251

  Sathler Avelar, Renato ^a   Vitelli Avelar, Danielle Marquete ^a   Teixeira Carvalho, Andréa ^a   Martins Filho, Olindo Assis ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Human Chagas disease; Innate immunity; Regulatory T cells

Indexed keywords

TRYPANOSOMA CRUZI;

EID: 68949220485     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000900031     Document Type: Article

References (48)

1. Antas PRZ, Araujo FF, Vitelli-Avelar DM, Gomes JAS, Sathler-Avelar R, Teixeira-Carvalho A, Elói-Santos SM, Pinho RT, Correa-Oliveira R, Martins-Filho AO 2009. Revisiting regulatory T cells: implications for the pathogenesis and management of human infections with emphasis in Chagas' disease. Microbes Infect, in press.
2. HIGH regulatory T cells in morbidity in Chagas disease. Front Biosci 12: 2797-2806.
3. High regulatory cells in human peripheral blood. J Immunol 167: 1245-1253.
4. Bahia-Oliveira LM, Gomes JA, Cançado JR, Ferrari TC, Lemos EM, Luz ZM, Moreira MC, Gazzinelli G, Correa-Oliveira R 2000. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J Infect Dis 182: 634-638.
5. ++monocytes are a major source of TNF. J Immunol 168: 3536-3542.
6. Bonney KM, Engman DM 2008. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 8: 510-518.
7. Brener Z, Gazzinelli RT 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 114: 103-110.
8. Buscaglia CA, Di Noia JM 2003. Trypanosoma cruzi clonal diversity and the epidemiology of Chagas disease. Microbes Infect 5: 419-427.
9. Camargo MM, Andrade AC, Almeida IC, Travassos LR, Gazzinelli RT 1997. Glycoconjugates isolated from Trypanosoma cruzi but not from Leishmania species membranes trigger nitric oxide synthesis as well as microbicidal activity in IFN-gamma-primed macrophages. J Immunol 159: 6131-6139.
10. Correa-Oliveira R, Gomes J, Lemos EM, Cardoso GM, Reis DD, Adad S, Crema E, Martins-Filho OA, Costa MO, Gazzinelli G, Bahia-Oliveira LM 1999. The role of the immune response on the development of severe clinical forms of human Chagas disease. Mem Inst Oswaldo Cruz 94 (Suppl. I): 253-255.
11. Coura JR, de Castro SL 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
12. da Silveira AB, Correa-Oliveira R, Matsuyama H, de Oliveira EC, Neto SG, Luquetti AO, Furness JB, d'Avila Reis D 2008. Decreased expression of IK channels in neurons from enteric nervous system is associated with the development of chagasic megacolon. Hum Pathol 39: 1406-1407.
13. Dutra WO, Martins-Filho OA, Cançado JR, Pinto-Dias JC, Brener Z, Freeman Júnior GL, Colley DG, Gazzinelli G, Parra JC 1994. Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. Int Immunol 6: 499-506.
14. Dutra WO, Martins-Filho OA, Cançado JR, Pinto-Dias JC, Brener Z, Gazzinelli G, Carvalho JF, Colley DG 1996. Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Scand J Immunol 43: 88-93.
15. Dutra WO, Rocha MO, Teixeira MM 2005. The clinical immunology of human Chagas disease. Trends Parasitol 21: 581-587.
16. Galvão LM, Nunes RM, Cançado JR, Brener Z, Krettli AU 1993. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 87: 220-223.
17. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A 1993. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 90: 6115-6119.
18. Godfrey DI, Kronenberg M 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114: 1379-1388.
19. Golgher D, Gazzinelli RT 2004. Innate and acquired immunity in the pathogenesis of Chagas' disease. Autoimmunity 37: 399-409.
20. Gomes JA, Bahia-Oliveira LM, Rocha MO, Busek SC, Teixeira MM, Silva JS, Correa-Oliveira R 2005. Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. Infect Immun 73: 7960-7966.
21. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R 2003. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun 71: 1185-1193.
22. Hontebeyrie-Joskowicz M, Minoprio P 1991. Chagas' disease: Trypanosoma cruzi vs. the host immune system. Res Immunol 142: 125-126.
23. Hori S, Nomura T, Sakaguchi S 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
24. Lemos EM, Reis D, Adad SJ, Silva GC, Crema E, Correa-Oliveira R 1998. Decreased CD4(+) circulating T lymphocytes in patients with gastrointestinal Chagas disease. Clin Immunol Immunopathol 88: 150-155.
25. Lieke T, Graefe SE, Klauenberg U, Fleischer B, Jacobs T 2004. NK-cells contribute to the control of Trypanosoma cruzi infection by killing free parasites by perforin-independent mechanisms. Infect Immun 72: 6817-6825.
26. Macedo AM, Machado CR, Oliveira RP, Pena SD 2004. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem Inst Oswaldo Cruz 99: 1-12.
27. Mady C, Ianni BM, de Souza JL Jr 2008. Benznidazole and Chagas disease: can an old drug be the answer to an old problem? Expert Opin Investig Drugs 17: 1427-1433.
28. Marinho CR, D'Império Lima MR, Grisotto MG, Alvarez JM 1999. Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Infect Immun 67: 308-318.
29. Michailowsky V, Murta SM, Carvalho-Oliveira L, Pereira ME, Ferreira LR, Brener Z, Romanha AJ, Gazzinelli RT 1998. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob Agents Chemother 42: 2549-2556.
30. Murray DA, Crispe IN 2004. TNF-alpha controls intrahepatic T cell apoptosis and peripheral T cell numbers. J Immunol 173: 2402-2409.
31. Piccirillo CA 2008. Regulatory T cells in health and disease. Cytokine 43: 395-401.
32. Ramsdell F 2003. FOXP3 and natural regulatory T cells: key to a cell lineage? Immunity 19: 165-168.
33. Read S, Malmström V, Powrie F 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+) CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192: 295-302.
34. Reis DD, Jones EM, Tostes S Jr, Lopes ER, Gazzinelli G, Colley DG, McCurley TL 1993. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+lymphocytes. Am J Trop Med Hyg 48: 637-644.
35. Samudio M, Montenegro-James S, Cabral M, Martinez J, Rojas de Arias A, James MA 1998. Cytokine responses in Trypanosoma cruzi infected children in Paraguay. Am J Trop Med Hyg 58: 119-121.
36. Sathler-Avelar R, Lemos EM, Reis DD, Medrano-Mercado N, Araújo-Jorge TC, Antas PR, Corrêa-Oliveira R, Teixeira-Carvalho A, Elói-Santos SM, Favato D, Martins-Filho OA 2003. Phenotypic features of peripheral blood leucocytes during early stages of human infection with Trypanosoma cruzi. Scand J Immunol 58: 655-663.
37. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho OA 2006. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol 64: 554-563.
38. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, de Lana M, Pinto Dias JC, Teixeira-Carvalho A, Elói-Santos SM, Martins-Filho OA 2008. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect 10: 103-113.
39. Souza PE, Rocha MO, Rocha-Vieira E, Menezes CA, Chaves AC, Gollob KJ, Dutra WO 2004. Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun 72: 5283-5291.
40. Teixeira MM, Gazzinelli RT, Silva JS 2002. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 18: 262-265.
41. Umezawa ES, Stolf AM, Corbett CE, Shikanai-Yasuda MA 2000. Chagas disease. Lancet 357: 797-799.
42. Urbina JA 1999. Chemotherapy of Chagas' disease: the how and the why. J Mol Med 77: 332-338.
43. Vago AR, Andrade LO, Leite AA, d'Avila Reis D, Macedo AM, Adad SJ, Tostes S Jr, Moreira MC, Filho GB, Pena SD 2000. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. Am J Pathol 156: 1805-1809.
44. High regulatory T lymphocytes. Scand J Immunol 62: 297-308.
45. +T cells, the key to control Chagas' disease morbidity? Clin Exp Immunol 145: 81-92.
46. Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A, Pinto Dias JC, Gontijo ED, Faria AM, Elói-Santos SM, Martins-Filho OA 2008. Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand J Immunol 68: 516-525.
47. Weekly ER 2007. New global efforts to eliminate Chagas disease. Report. WER 82: 259-260.
48. +blood monocytes: their role in infection and inflammation. J Leukoc Biol 81: 584-592.